Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Gunst JD, 2021 NCT04321096

camostat mesilate (n=139) vs. placebo (n=69)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Camostat Mesilate
2x100 mg pills 3 times daily (every 8h) for 5 days.

Control treatment

placebo
2 pills 3 times daily for 5 days.

2:1 ratio. Some patients received remdesivir and/or dexamethasone as standard of care. All participants also received prophylactic or therapeutic anticoagulatory treatment.

Patients

COVID 19 all comers

documented COVID-19 infection as evidenced by positive PCR (or comparable clinical assay) for SARS-coV-2 ; less than 48 hours since time of hospital admission OR if hospital-acquired COVID-19 is suspected, less than 48 hrs since onset of symptoms

Method

Double-blind

Denmark (8 sites), Sweden (1 site).

Phase IIa. The scale consisted of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring high-flow oxygen therapy or noninvasive ventilation;6, hospitalized, requiring invasive mechanical ventilation; and 7,death. After discharged, phone interviews were conducted up to day 30 to monitor treatment adherence and clinical status.

Remark